🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

NEWS: AbbVie has recently published real-world data in #AJH evaluating BCL2i-based therapy after BTKi treatment in #CLL. For more information bit.ly/40Arfqk Toby Eyre, calliecoombs Alan Skarbnik Matthew Davids, MD, MMSc #leusm

People-centered care is critical for those impacted by cancer. As #WorldCancerDay approaches, we’re sharing our commitment to creating targeted medicines to personalize care for patients. Learn more: abbvie.com/science/areas-… #UnitedByUnique

Recently published in @nature: Our preclinical work identifying a synthetic lethal interaction between two protein complexes that may offer novel therapeutic targets in #oncology. Learn more: go.nature.com/4hYH2oI

Clinical data evaluating @Abbvie’s investigational drug as combination therapy in relapsed/refractory diffuse large B-cell #lymphoma (#DLBCL) patients who are transplant-ineligible is now published in Blood Journal, in partnership with Genmab. Learn more:bit.ly/4gUOC34

NEWS: 🔬Available now in Blood Advances: MURANO study: final analysis and retreatment/crossover substudy results of BCL2i plus anti-CD20 mAB for patients with R/R #CLL For more information: bit.ly/3DvsQVM #leusm

JUST IN: We’re presenting new data at #AACR25 showcasing our early pipeline and research in oncology to help advance the science across a range of #cancers with high unmet needs. Read more: bit.ly/423SNE4

Here at @AbbVie, we remain committed to advancing oncology research and are proud to share 28 AbbVie abstracts, including 4 orals, across 15 disease states at #ASCO25 bit.ly/45zcYNA

Join us at #ASCO25 as @AbbVie presents clinical updates in #MultipleMyeloma research and development. Abstracts can be found at the ASCO abstract hub: bit.ly/3HzbFUN #mmsm

Join us to see an @AbbVie #lymphoma abstract on Friday at #EHA2025 Abstract PF885: R/R FL Lorenzo Falchi, MD, Martin Hutchings, Dr Kim Linton et al You can find this scientific abstract here: bit.ly/43FI2dd #LYMSM

At #EHA25, @AbbVie presents preliminary results are presented on the ongoing Phase 2 study of retreatment with #BCL2i + CD20 mAB in patients with recurrent #CLL bit.ly/449bLvj #leusm

Join us to see an @AbbVie #FL abstract on Thursday at #18ICML Abstract 241: 2L+ FL MAIC You can find this scientific abstract here: bit.ly/3HN4qZz #LYMSM

Join us to see @AbbVie #lymphoma abstracts on Friday at #18ICML Abstract 216: CD3 x CD20 bispecific antibody monotherapy in R/R CLL Abstract 248: 2L+ FL MAIC You can find these scientific abstracts here: bit.ly/465zdej #LYMSM